FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
16.0 pts (24h)GeopoliticsOne-OffHealth & Medicine3mo
KalshiCheck availabilityKYC required2% feeVerified resolution dataFairly calibratedCurrent implied probability
Yes 98%+16.0pt
Market quality
44 / 100
Low quality24h Volume
$593.9
Liquidity
$182.1
Low liquidityBid / Ask
80.0% / 88.0%
Spread
8.0 pt
Wide spreadMarket data
Updated 5 minutes ago
Jun 17, 26, 9:00 PM UTCJan 1, 27, 4:59 AM UTC
Trends
Related Markets
Related questions for context, not a comparison of equivalent contracts.
FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
KalshiFDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
KalshiFDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
KalshiDid COVID-19 come from a laboratory?
Manifold MarketsWhich states will report local cases in the May 2026 Ebola Bundibugyo outbreak
Manifold MarketsWhen, where or how will Trump die?
Manifold MarketsRules
If the FDA's decision on Ifinatamab Deruxtecan by Daiichi Sankyo in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Settles via:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Ifinatamab deruxtecan (also called I-DXd or DS-7300) is an antibody-drug conjugate — think of it as a guided missile where a targeting protein is chemically linked to a potent cancer-killing payload.
- The targeting protein homes in on a molecule called B7-H3 (also known as CD276), which appears in unusually high amounts on the surface of many cancer cells, and once the drug locks onto that target it is pulled inside the cell and releases its toxic payload.
- In doing so, it aims to kill tumor cells more precisely than traditional chemotherapy, which attacks both healthy and cancerous cells indiscriminately.
Open markets
Geopolitics
POLYMARKETWhich party will gain most seats in Russian Parliamentary Election?
- United Russia (ER)+5.0pt74.3%
- New People (NL)-3.8pt21.8%
- Liberal Democratic Party of Russia (LDPR)-0.9pt3%
+5 more outcomes
- Total Vol
- $25.8M
- 24h Vol
- $574.8K
POLYMARKETUS announces end of Iranian blockade by which date?
- December 31-3.1pt48.3%
- October 31-3.0pt28.9%
- September 30-4.0pt12.3%
+17 more outcomes
POLYMARKETKharg Island no longer under Iranian control by which date?
- December 317%
- September 30+0.4pt2%
- July 310%
+7 more outcomes
- Total Vol
POLYMARKETUS x Iran Effective Ceasefire begins by...? (2 week pause)
- September 30-4.0pt75%
- September 18-7.0pt69%
- September 11-13.0pt57%
+2 more outcomes
POLYMARKETWill China invade Taiwan by end of 2026?
- No-0.1pt96%
- Yes+0.1pt4%
- Total Vol
- $41.1M
- 24h Vol
- $109.5K
POLYMARKETIsrael x Iran ceasefire continues through which date?
- July 18+0.3pt100%
- July 20+0.1pt100%
- July 22+0.5pt100%
+20 more outcomes
- Nobel Peace Prize Winner 2026
- US-Iran nuclear deal?
- Russia x Ukraine peace talks by which date?
- Strait of Hormuz traffic returns to normal by December 31?
- Will the U.S. invade Iran before 2027?
- Bab el-Mandeb Strait effectively closed by which date?
- Russia x Ukraine ceasefire agreement by which date?
- Will the Iranian regime fall by September 30?
- Iran-Oman Hormuz Management Agreement by which date?
- US-Iran Final Nuclear Deal by which date?
Frequently asked questions
- What are the current odds for FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)?
- Kalshi prices Yes at 98% as of September 8, 2026.
- When does FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026) resolve?
- FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026) is scheduled to resolve on January 1, 2027.
- How is FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026) settled?
- Kalshi settles this market as follows: If the FDA's decision on Ifinatamab Deruxtecan by Daiichi Sankyo in 2026 is a full approval or an accelerated approval, the market resolves to Yes.